Vision Care Direct of Oklahoma’s Post

Please check out this ReCAP covering important talks about the treatment of Wet AMD, DME and DR from ASRS – American Society of Retina Specialists 2024 meeting! Here I discuss the 4 important talks given at the meeting - LUNA Phase 2, PRISM Phase 2 Population Extension Cohort, RHONE-X: the largest DME extension study ever done, and Phase 1 HELIOS DR Study! A big thank you to Erica Zolberg and the Medscape team for creating this independent content to educate and inform retina specialists about key takeaways from ASRS 2024! #clinicaltrials #clinicalresearch #ReCAP #genetherapy #TKIs

As we mark #ParkinsonsAwarenessMonth, we are proud to share significant progress in our a-synuclein PET tracer program, bringing us closer to an imaging agent for the diagnosis of Parkinson’s Disease. ACI-12589 has proven specific and selective for a-syn, enabling us to visualize a-syn pathology in humans for the first time—a game changer for diagnosing multiple system atrophy and a leap towards #PrecisionMedicine. As we continue this journey, we are further leveraging our Morphomer platform to develop an imaging agent specifically optimized for #ParkinsonsDisease. Promising candidates such as ACI-15916 effectively bind to both large and smaller a-synuclein aggregates – crucial for detecting toxic proteins associated with Parkinson’s. The next-generation #asyn-PET tracer for PD is a critical step towards understanding and treating these complex diseases, much like how Abeta-PET has propelled Alzheimer’s clinical development. We are paving new paths in PD & MSA research, bringing hope to those affected by Parkinson's and MSA. For more details on our efforts to deliver the first PD tracer, watch Francesca Capotosti’s full presentation here: https://lnkd.in/gr6T5qK8 #ParkinsonsAwareness #NeurodegenerativeDiseases 

📢 NEWS ❗ ❗ Prof. Pengcheng Ma’s team’s study highlights the importance of the #Smurf1- and #Smurf2-#RNF220 axes during the pathogenesis of Shh-MB and provides new therapeutic targets for #Shh-MB treatment. https://lnkd.in/giYGipmE

Geographic atrophy from #maculardegeneration can be devastating to patients causing irreversible vision loss. Thankfully, new treatments have been recently approved and many trials are ongoing. Here is a quick review of those research trials for the treatment of geographic atrophy: #eyecare #optometrist #optometry https://lnkd.in/eKNMYnPs

We are excited to delve into the future of heart failure treatment without biopsies on Excellence Talks! Thank you, Murat Aydin, for your leadership and support of precision cardiac medicine efforts at InvivoSciences. Join me in exploring InvivoScience's and Ayla's journey, which is dedicated to healthcare innovation and improving patients' lives globally. 🔹 What milestones has she achieved in precision medicines for genetically defined heart failures, and what significant challenges did InvivoSciences overcome in this journey? 🔹 What's essential for reaching InvivoSciences' pending milestones in drug programs, and how does Ayla plan to address these needs? 🔹 How does InvivoSciences innovate precision cardiology for HFpEF cardiac disease, bridging the gap from current methods? #PrecisionMedicine #HealthcareInnovation #Cardiology#InvivoSciences #excellencetalks

✨ Exciting session alert at the #SLDSummit! Delve into the world of liver biopsy in MASLD research. Is 'biopsy bashing' justified? Discover its potentials, limitations, and how we can enhance its value for clinical trials. Explore its expanded applications and future prospects. Don't miss this discussion on bridging the gap between research and practice! 👉 easl.eu/sld2023

We are excited to delve into the future of heart failure treatment without biopsies on Excellence Talks! Thank you, Murat Aydin, for your leadership and support of precision cardiac medicine efforts at InvivoSciences. Join me in exploring InvivoScience's and Ayla's journey, which is dedicated to healthcare innovation and improving patients' lives globally. Here are some key questions we discussed: 🔹 Why did Ayla co-found InvivoSciences, and what fuels the company's mission? 🔹 What milestones has she achieved in precision medicines for genetically defined heart failures, and what significant challenges did InvivoSciences overcome in this journey? 🔹 What's essential for reaching InvivoSciences' pending milestones in drug programs, and how does Ayla plan to address these needs? 🔹 How does InvivoSciences innovate precision cardiology for HFpEF cardiac disease, bridging the gap from current methods? #PrecisionMedicine #HealthcareInnovation #Cardiology #InvivoSciences #excellencetalks

Want to explore the future of heart failure treatment without the need for biopsies? Join me on Excellence Talks. InvivoSciences and its co-founder/CEO Ayla's dedication to advancing healthcare through innovation and improving patients' lives worldwide is truly inspiring. Join me as we delve into her insights and experiences, exploring InvivoSciences' mission and the quest for precision medicine on Excellence Talks. Here are some questions we have discussed: 🔹 Why did Ayla co-found InvivoSciences, and what drives the company's mission? 🔹 What key milestones has she achieved in developing precision medicines for genetically defined heart failures, and what challenges has she encountered? 🔹 What is needed to achieve the pending milestones of InvivoSciences' drug program, and how does Ayla plan to address these needs? 🔹 How does precision cardiology approach HFpEF cardiac disease differently from current methodologies, and how does InvivoSciences bridge this gap? Don't miss this opportunity to learn from a leader in the field. Watch the video below to gain valuable insights into the future of heart failure treatment. #PrecisionMedicine #HealthcareInnovation #Cardiology #InvivoSciences #excellencetalks #technology@heartfailureforpreservedejection

We want to recognize ALCORIX CO on their recent #NINDS #STTR Phase 2 award. Their STTR proposal entitled "Implantable Microarray Probe for Real-Time Glutamate and GABA Detection" will focus on developing and testing a novel, first-on-the-market implantable biosensor for in vivo, real-time sensing of gamma-aminobutyric acid (#GABA) and #glutamate (GLU) for animal studies.  GLU-GABA dysregulation plays a critical role in several brain disorders, including #epilepsy, #dementia and #parkinsonsdisease. 

📣 We are thrilled to announce our participation in the leading Spanish Hepatology Congress, by Asociación Española del Estudio del Hígado, where we have presented an original scientific poster.  🆕 This new research is the result of our R&D team, focused on developing an improved culture model using human precision-cut liver slices (hPCLS) to investigate the phenotype and functionality of the hepatic sinusoid in the context of chronic liver disease. By using our patent-protected chip with microfluidics, we are able to culture hPCLS with: ✔ Extended half-life, up to 7 days. ✔ Enhanced structural and functional integrity of the tissue. ✔ Prevention of the loss of the sinusoidal cell phenotype. This model represents a new research tool that brings us closer to clinical applications compared to traditional models 🚀  #AEEH2024 #Liver #Sinusoid #Hepatology #Cirrhosis #ACLD #PCLS #3Dmodel #Scientificinnovation